Tamás Resál
YOU?
Author Swipe
View article: Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn’s Disease: A Retrospective, Multicentre Study
Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn’s Disease: A Retrospective, Multicentre Study Open
Background/Objectives: Data on the real-world effectiveness and safety of selective JAK inhibitors (JAKis) in ulcerative colitis (UC) and Crohn’s disease (CD) are limited. Methods: We conducted a multicentre, retrospective study to assess …
View article: Evaluation of the Effectiveness and Safety of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease: An International Real‐Life Retrospective Multicentre Cohort Study
Evaluation of the Effectiveness and Safety of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease: An International Real‐Life Retrospective Multicentre Cohort Study Open
Background Perianal fistulas of Crohn's disease (CD) create a significant burden on patients' lives. However, the efficacy and safety of adipose‐derived mesenchymal stem cell treatment are contradicting, and real‐world evidence is lacking.…
View article: Long-term outcomes after endoscopic removal of malignant colorectal polyps: Results from a 10-year cohort
Long-term outcomes after endoscopic removal of malignant colorectal polyps: Results from a 10-year cohort Open
BACKGROUND Choosing an optimal post-polypectomy management strategy of malignant colorectal polyps is challenging, and evidence regarding a surveillance-only strategy is limited. AIM To evaluate long-term outcomes after endoscopic removal …
View article: Long-term outcomes after endoscopic removal of malignant colorectal polyps: results from a 10-year cohort
Long-term outcomes after endoscopic removal of malignant colorectal polyps: results from a 10-year cohort Open
Methods A single-center retrospective cohort study was conducted to evaluate outcomes after endoscopic removal of malignant colorectal polyps between 2010 and 2020. Residual disease rate and nodal metastases after secondary surgery; and lo…
View article: Szűrő kolonoszkópos vizsgálatok hatékonyságának és biztonságosságának értékelése a Szegedi Tudományegyetemen és a Bács-Kiskun Vármegyei Oktatókórházban 2019 és 2022 között
Szűrő kolonoszkópos vizsgálatok hatékonyságának és biztonságosságának értékelése a Szegedi Tudományegyetemen és a Bács-Kiskun Vármegyei Oktatókórházban 2019 és 2022 között Open
Bevezetés: Magyarországon 2019-ben indult az 50–70 éves populáció körében a kétlépcsős vastagbélszűrő program, melynek célja a colorectalis carcinoma kialakulásának megelőzése. Célkitűzés: Kutatásunk célja volt a Szegedi Tudományegyetemen …
View article: P560 The impact of reactive point-of-care drug level measurement on the medium-term course of inflammatory bowel disease
P560 The impact of reactive point-of-care drug level measurement on the medium-term course of inflammatory bowel disease Open
Background First generation of biologicals (infliximab (IFX) and adalimumab (ADA)) has revolutionised the treatment of patients with Crohn’s disease (CD) and ulcerative colitis (UC), however, primary resistance or loss of efficacy are seri…
View article: P1016 Real-world data on sequential therapy in moderate-to-severe UC: Unveiling second-line strategies after anti-TNF failure
P1016 Real-world data on sequential therapy in moderate-to-severe UC: Unveiling second-line strategies after anti-TNF failure Open
Background The development of anti-TNFs has brought major advances in the treatment of ulcerative colitis (UC). Yet, a significant proportion of patients do not respond favorably to first-line anti-TNF therapy, which may require the use of…
View article: Accuracy of the Pancolonic Modified Mayo Score in predicting the long-term outcomes of ulcerative colitis: a promising scoring system
Accuracy of the Pancolonic Modified Mayo Score in predicting the long-term outcomes of ulcerative colitis: a promising scoring system Open
Background: Different endoscopic scoring systems for assessing ulcerative colitis (UC) severity are available. However, most of them are not correlated with disease extent. Objectives: Our study aimed to compare the predictive value of the…
View article: Comparison of risk of malignancy and predictive value of diagnostic categories defined by Papanicolaou Society of Cytopathology system and WHO reporting system for pancreaticobiliary cytopathology in solid pancreatic lesions
Comparison of risk of malignancy and predictive value of diagnostic categories defined by Papanicolaou Society of Cytopathology system and WHO reporting system for pancreaticobiliary cytopathology in solid pancreatic lesions Open
Background: The standardized diagnostic categories defined by the World Health Organization (WHO) reporting system support the interdisciplinary interpretation of cytological findings in the management of pancreatic cancer. Objective: To c…
View article: P938 Effectiveness and safety of switching from original infliximab to GP1111 biosimilar in inflammatory bowel diseases – prospective, cohort study
P938 Effectiveness and safety of switching from original infliximab to GP1111 biosimilar in inflammatory bowel diseases – prospective, cohort study Open
Background Biosimilars are highly similar to the already approved reference biological medication, and are potentially more accessible widespread due to the better cost-effectiveness. However, both the effectiveness and immunogenicity may …
View article: Az anémia etiopatológiája, diagnózisa és kezelése gyulladásos bélbetegségekben
Az anémia etiopatológiája, diagnózisa és kezelése gyulladásos bélbetegségekben Open
Az anémia az egyik leggyakoribb komorbiditás gyulladásos bélbetegeknél (IBD), amelynek a hátterében leggyakrabban a vasháztartás zavara áll. Bár az anémia prevalenciája kifejezetten magas, és az életminőséget is jelentősen rontja, a pontos…
View article: P674 Real-world experiences of switching to subcutaneous formulation in IBD patients on maintenance vedolizumab treatment
P674 Real-world experiences of switching to subcutaneous formulation in IBD patients on maintenance vedolizumab treatment Open
Background Usability of subcutaneous vedolizumab (SC VDZ) in inflammatory bowel diseases (IBD, ulcerative colitis [UC], Crohn’s disease [CD]) have proved via clinical trials, while real-world data collection is ongoing. Experiences of Cent…
View article: P421 The faecal biomarker LDN-051 is a novel tool for monitoring disease activity and therapeutic response in Inflammatory Bowel Diseases
P421 The faecal biomarker LDN-051 is a novel tool for monitoring disease activity and therapeutic response in Inflammatory Bowel Diseases Open
Background Crohn’s disease and ulcerative colitis, two forms of inflammatory bowel disease (IBD) require lifelong treatment and patient monitoring. Current predictors of relapse and therapeutic success have limitations, therefore there is …
View article: Outcomes of treatment cessation after switching to subcutaneous vedolizumab treatment in inflammatory bowel diseases
Outcomes of treatment cessation after switching to subcutaneous vedolizumab treatment in inflammatory bowel diseases Open
Background: The usability of subcutaneous vedolizumab (s.c. VDZ) treatment in inflammatory bowel diseases (IBD; ulcerative colitis (UC), Crohn’s disease (CD)) has been proven via clinical trials while real-world data collection is ongoing.…
View article: P356 Long-term outcome of UC patients in clinical remission with different level of mucosal activity: real world, retrospective, multicontinental study
P356 Long-term outcome of UC patients in clinical remission with different level of mucosal activity: real world, retrospective, multicontinental study Open
Background In contrast to the increasingly rigorous endpoints of clinical trials of ulcerative colitis (UC), Mayo endoscopic score (MES) ≤ 1 is mostly set as target during clinical follow-up, but long-term outcomes may differ according to …
View article: Plasminogen Activator Inhibitor 1 Is a Novel Faecal Biomarker for Monitoring Disease Activity and Therapeutic Response in Inflammatory Bowel Diseases
Plasminogen Activator Inhibitor 1 Is a Novel Faecal Biomarker for Monitoring Disease Activity and Therapeutic Response in Inflammatory Bowel Diseases Open
Background and Aims Crohn’s disease [CD] and ulcerative colitis [UC] require lifelong treatment and patient monitoring. Current biomarkers have several limitations; therefore, there is an unmet need to identify novel biomarkers in inflamma…
View article: Risk Factors and Interpretation of Inconclusive Endoscopic Ultrasound-Guided Fine Needle Aspiration Cytology in the Diagnosis of Solid Pancreatic Lesions
Risk Factors and Interpretation of Inconclusive Endoscopic Ultrasound-Guided Fine Needle Aspiration Cytology in the Diagnosis of Solid Pancreatic Lesions Open
Background: The inconclusive cytological findings of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) remain a major clinical challenge and often lead to treatment delays. Methods: Patients who had undergone EUS-FNA sampling f…
View article: Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study
Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study Open
Background and Aims Tofacitinib (TFB) appears to be effective in the treatment of ulcerative colitis (UC); however, available real-world studies are limited by cohort size. TFB could be an option in the treatment of acute severe ulcerative…
View article: Az alsó tápcsatornai endoszkópos ultrahangvizsgálat
Az alsó tápcsatornai endoszkópos ultrahangvizsgálat Open
Az endoszkópiát és az ultrahangtechnikát ötvöző, a tápcsatorna falának és a környező szerveknek és szöveteknek a vizualizálására minimálisan invazív módon alkalmas endoszkópos ultrahangvizsgálat az 1980-as évekbeli kifejlesztése óta jelent…
View article: Letter: Experience of switching vedolizumab treatment from intravenous to subcutaneous formulation in Hungary
Letter: Experience of switching vedolizumab treatment from intravenous to subcutaneous formulation in Hungary Open
LINKED CONTENT This article is linked to Volkers et al paper. To view this article, visit https://doi.org/10.1111/apt.17153
View article: Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease: results of a multicenter survey
Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease: results of a multicenter survey Open
Subjective efficacy of switching to a biosimilar was proven in case of ADA, while reduced efficacy was experienced with IFX biosimilar. Perception of AEs was high and varied between biosimilars.
View article: P605 Real life efficacy of tofacitinib in different situation in ulcerative colitis: a retrospective worldwide multicentre collaborative study
P605 Real life efficacy of tofacitinib in different situation in ulcerative colitis: a retrospective worldwide multicentre collaborative study Open
Background The orally administered small molecule drug pan-Jak inhibitor tofacitinib (TFB) appears to be effective in the treatment of ulcerative colitis (UC), however, available real world studies are limited by the cohort size. In additi…
View article: DOP13 Plasma metabolite fingerprint could discriminate inflammatory bowel disease patients from healthy subjects
DOP13 Plasma metabolite fingerprint could discriminate inflammatory bowel disease patients from healthy subjects Open
Background Inflammatory bowel diseases (IBD, Crohn’s disease [CD], ulcerative colitis [UC]) are chronic immune-mediated systemic diseases with unknown aetiology. In the past few years, experimental studies revealed associations of human se…
View article: P184 Identification of the PAI-1, as a potential non-invasive, fecal biomarker in the Inflammatory Bowel Diseases
P184 Identification of the PAI-1, as a potential non-invasive, fecal biomarker in the Inflammatory Bowel Diseases Open
Background Inflammatory bowel diseases (IBD) are defined by unregulated immune response leading to intestinal inflammation. Monitoring of the intestinal inflammation are mostly invasive, time-consuming and expensive. Therefore, a simple, r…
View article: P309 Accuracy of PanMayo endoscopic score in predicting long-term disease outcomes in ulcerative colitis– a promising scoring system
P309 Accuracy of PanMayo endoscopic score in predicting long-term disease outcomes in ulcerative colitis– a promising scoring system Open
Background Ulcerative colitis (UC) is a systemic immune-mediated disease that affects the colon continuously. Colonoscopy plays a crucial role in management of UC that helps to assess mucosal healing objectively along the colon. Different …
View article: P739 Sequential treatment is effective to achieve remission and avoid colectomy in moderate-to-severe Ulcerative Colitis refractory to anti-TNF therapy
P739 Sequential treatment is effective to achieve remission and avoid colectomy in moderate-to-severe Ulcerative Colitis refractory to anti-TNF therapy Open
Background The development of anti-TNF agents has brought advances in the treatment of ulcerative colitis (UC). However, many patients require biological treatment sequencing. We aimed to evaluate clinical outcomes, the rate of treatment p…
View article: P797 Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with Inflammatory Bowel Disease: Results of a multicenter survey
P797 Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with Inflammatory Bowel Disease: Results of a multicenter survey Open
Background Several studies have proven similarity in terms of efficacy and safety between infliximab (IFX) or adalimumab (ADA) biosimilars and their corresponding originators. However, there is still a paucity of data on the impact of swit…
View article: Burnout among European IBD specialists: a survey supported by ECCO
Burnout among European IBD specialists: a survey supported by ECCO Open
Background: Burnout remains a significant health concern within the healthcare sector. Numerous studies have explored burnout among gastroenterologists. However, as far as we are aware, there is currently no documented research specificall…
View article: Psychological characteristics of patients with inflammatory bowel disease during the first wave of COVID-19
Psychological characteristics of patients with inflammatory bowel disease during the first wave of COVID-19 Open
Patients need more attention during this period to help them cope with psychological factors and prevent their IBD from becoming worse.
View article: Effects of bowel cleansing on the composition of the gut microbiota in inflammatory bowel disease patients and healthy controls
Effects of bowel cleansing on the composition of the gut microbiota in inflammatory bowel disease patients and healthy controls Open
Background: In patients with inflammatory bowel disease (IBD), Crohn’s disease (CD), and ulcerative colitis (UC), numerous cases of exacerbations could be observed after colonoscopy, raising the possible pathogenetic effect of colonic micr…